We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia.
- Authors
Gelhorn, Heather L; Boye, Kristina S; Shalhoub, Huda; Matza, Louis S; Jordan, Jessica B; Alhammad, Ali; Anand, Savita B; Ekhzaimy, Aishah A; Strizek, Alena
- Abstract
aimy,5 Alena Strizek61Evidera, Bethesda, MD, USA; 2Eli Lilly and Company, Indianapolis, IN, USA; 3Eli Lilly and Company, Riyadh, Kingdom of Saudi Arabia; 4Evidera, London, UK; 5King Saud University, King Saud University Medical City, Riyadh, Kingdom of Saudi Arabia; 6Eli Lilly, Sydney, AustraliaCorrespondence: Heather L GelhornEvidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, MD 20814, USATel +1 970-363-7333Email heather.gelhorn@evidera.com Background: The Kingdom of Saudi Arabia (KSA) has the second highest prevalence of type 2 diabetes mellitus (T2DM) in the Middle East. There is a paucity of research on the experiences and treatment preferences of patients with T2DM in KSA. This study explored Saudi patients' health-related quality of life, eating habits, experiences during Ramadan, and preference between two glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment devices. Methods: A cross-sectional, observational study was conducted in three cities in KSA. Participants completed sociodemographic and clinical forms, EQ-5D-5L, Impact of Weight on Self-Perceptions, and a diabetes treatment survey. Participants also viewed instructional videos on GLP-1 RA injection devices and indicated their device preference. Results: Of the 310 participants, 53% were male. The mean age was 43 years (range: 30.0– 75.0), duration since diabetes diagnosis was 6.3 years (range: 0.2– 27.1), the most commonly reported last HbA1c level was between ≥ 7.1% and 8% (45%). The mean EQ-5D-5L index score was 0.90, with some participants reporting problems with pain/discomfort (34.5%) and usual activities (33.2%). Patients reported a low-to-moderate impact of weight on self-perception. In preparation for Ramadan, participants sought physician advice on diabetes management (37%) and/or increased checks of their blood glucose (37%). After watching the videos, 89% (n=277) of participants indicated a device preference, with significantly more preferring the dulaglutide device (n=186, 67%) over the semaglutide device (n=91, 33%) (p< 0.0001). Conclusion: This study indicates that T2DM has a significant social, emotional, and behavioral impact on the lives of patients in KSA.
- Subjects
SAUDI Arabia; TYPE 2 diabetes; KING Saud University; GLUCAGON-like peptide-1 receptor; GLUCAGON-like peptide-1 agonists; PATIENT preferences; CROSS-sectional method
- Publication
Patient Preference & Adherence, 2020, Vol 14, p2231
- ISSN
1177-889X
- Publication type
Article
- DOI
10.2147/PPA.S265126